Aleksandra M.
- Country
- Poland
- Department
- Oddział Kliniczny Hematologii i Profilaktyki Chorób Nowotworowych
Research Overview
Data & Insights
Has run more than one trial at 2 of 44 partner sites.
Specializations
Hematologic malignancies
Clinical work centers on lymphoid cancers, with involvement in chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and diffuse large B-cell lymphoma. The trial portfolio also reflects interest in broader B-cell malignancies and aggressive lymphoma subtypes.
- Chronic lymphocytic leukemia
- Diffuse large B-cell lymphoma
- Mantle cell lymphoma
- Follicular lymphoma
- Marginal zone lymphoma
Research activity also includes Waldenström macroglobulinemia and other indolent-to-aggressive lymphoma settings, indicating a strong focus on blood cancer management within the hematology department.
Multiple myeloma and plasma cell disorders
Another major area of interest is multiple myeloma, including relapsed and refractory disease. The investigator is involved in studies addressing treatment optimization for plasma cell malignancies and related bone marrow-based disorders.
- Multiple myeloma
- Relapsed/refractory myeloma
- Plasma cell malignancies
This domain connects with research on combination therapies used to improve disease control in patients with advanced myeloma.
Acute leukemias
The investigator is also active in acute myeloid leukemia and acute lymphoblastic leukemia, including molecularly defined subgroups and pediatric-onset disease. This area spans both newly diagnosed and difficult-to-treat leukemia settings.
- Acute myeloid leukemia
- Acute lymphoblastic leukemia
- FLT3-mutated AML
- KMT2A-rearranged ALL
Interest in molecularly guided leukemia therapy and subtype-specific treatment strategies is evident from the clinical trial portfolio.
Targeted therapy and immunotherapy in blood cancers
Clinical research includes therapies directed at B-cell lymphoproliferative disorders, with emphasis on agents used in BTK inhibition, BCL-2 inhibition, and antibody-based treatment approaches. The portfolio also includes interest in long-term treatment access and sustained disease control.
- BTK inhibitor-based therapy
- BCL-2 inhibitor-based therapy
- Antibody-based regimens
- B-cell non-Hodgkin lymphoma
These activities place a strong therapeutic emphasis on modern targeted approaches for hematologic oncology.
Non-hematologic oncology and transplant-related disease
Beyond blood cancers, the investigator has involvement in urothelial carcinoma and breast cancer, as well as graft-versus-host disease, reflecting a wider oncology and post-transplant interest profile.
- Urothelial carcinoma
- Breast cancer
- Graft-versus-host disease
This range links solid tumor care with transplant-associated complications in a clinical setting focused on cancer and hematologic disease.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.